Peregrine Pharmaceuticals, Inc. (PPHM) Receives New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Peregrine Pharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent Number No. 7,455,833 to the company. This patent includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. According to the press release, the aminophospholipid family of phospholipids represents a novel target for anti-viral therapies. Steven W. King, president and CEO of Peregrine, commented, “Issuance of this broad anti-viral patent significantly expands our intellectual property leadership the field of phospholipid-targeting antibodies. Antibodies falling under the scope of this new patent are already showing promise in preclinical studies of lethal virus diseases including hemorrhagic fever…